You just read:

iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3Kδ Inhibitor, IOA-244 for Solid Tumours

News provided by

iOnctura

26 Feb, 2020, 08:00 GMT